| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allovir, Inc. | Director | Common Stock | 252,000 | $2,539,102 | $10.08 | 18 Mar 2025 | Direct |
| Allovir, Inc. | Director | Common Stock | 100,800 | $1,015,641 | $10.08 | 18 Mar 2025 | Indirect |
| Kalaris Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 18,000 | 10 Apr 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | 10 Apr 2025 | 1 | $0 | 4 | Director | 11 Apr 2025, 17:04 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 3 | $0 | 4 | Director | 18 Mar 2025, 17:44 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 0 | $0 | 3 | Director | 18 Mar 2025, 17:21 |